<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04677803</url>
  </required_header>
  <id_info>
    <org_study_id>BT200-02</org_study_id>
    <nct_id>NCT04677803</nct_id>
  </id_info>
  <brief_title>BT200 in Hereditary Bleeding Disorders</brief_title>
  <official_title>A Phase 2a Multiple Dose Basket Study of the Safety, Tolerability, and Pharmacologic Activity of BT200 in Patients With Hereditary Bleeding Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BT200 is a PEGylated aptamer that binds to the A1 domain of human von Willebrand factor&#xD;
      (VWF). At low doses, BT200 blocks the clearance of VWF antigen (VWF Ag) from the circulation&#xD;
      and causes an increase in concentrations of both VWF Ag and Factor VIII (FVIII), but has&#xD;
      negligible effect on the activity of either. At higher doses, BT200 blocks clearance of VWF&#xD;
      and also inhibits its activity, but still does not inhibit FVIII activity. Therefore, low&#xD;
      dose BT200 could potentially be used to correct deficiency of VWF and/or FVIII in patients&#xD;
      with hereditary bleeding disorders. This study is designed as a &quot;basket design&quot; pilot study&#xD;
      to determine the relevant dose and pharmacological activity of BT200 in such patients.&#xD;
&#xD;
      In this open basket study up to 25 patients with the following congenital blood-clotting&#xD;
      disorders are to be included: Patients with hemophilia A, heterozygous carriers of hemophilia&#xD;
      A with subnormal FVIII levels; patients with von Willebrand syndrome (VWD) type 1, &quot;Vicenza&#xD;
      type&quot;, and with VWD type 2b.&#xD;
&#xD;
      Participants will receive BT200 subcutaneously on day 0, day 4 and day 7 in the first week&#xD;
      and then once a week for a total of five weeks - initially in a dose of 3 mg, then in week 3&#xD;
      individually after response in a dose of 3 to 9 mg.&#xD;
&#xD;
      Subsequently, blood samples are taken once a week for a further three weeks (wash-out phase).&#xD;
&#xD;
      Patients may be enrolled in an additional pharmacokinetics sub-study. For this purpose,&#xD;
      approximately three blood samples are taken to estimate the half-life of substituted FVIII&#xD;
      under the influence of BT200.&#xD;
&#xD;
      The primary objective of this study is to obtain clinical proof of mechanism for BT200 in one&#xD;
      or more hereditary bleeding disorders.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Actual">September 10, 2021</completion_date>
  <primary_completion_date type="Actual">September 10, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, individual dose titration-to-response, basket trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemophilia A</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>increase in FVIII activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VWD Type 1</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>increase in FVIII activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VWD Type 2b</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>increase in platelet count and/or FVIII activity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Measured concentration of BT200 (and derived PK parameters)</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Measured concentration of BT200</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>PFA-100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Multiplate electrode platelet aggregometer (ristocetin induced)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>VWF antigen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>VWF:ristocetin co-factor assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>VWF activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>VWF collagen bindign assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>ELISA for unbound VWF-A1 domain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>VWF propeptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Fibrin D-Dimer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Prothrombin fragement (F1.2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Rotational thrombelastometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Clot strength assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Calibrated Thrombogram assay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall safety and tolerability of BT200</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Serious, drug-related adverse events (AEs)</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall safety and tolerability of BT200</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Patterns of serious or non-serious, drug-related AEs and/or clinically relevant laboratory abnormalities, vital signs, or physical findings suggestive of one or more specific target organs for toxicity of BT200</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall safety and tolerability of BT200</measure>
    <time_frame>Baseline through 4 weeks after dosing</time_frame>
    <description>Clinically evident bleeding assessed using the International International Society on Thrombosis and Haemostasis (ISTH) Bleeding Score</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Von Willebrand Diseases</condition>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous (SC) injection:&#xD;
BT200 dose 3 mg on Day 0, Day 4, and again on Day 7 BT200 dose titrated thereafter between 3 and 9 mg on Days 14, 21, and 28. It is anticipated that dose adjustments will be performed in 2 mg steps. The 9 mg dose will only be applied on day 28 in exceptional circumstances, if no relevant changes in pharmacodynamic and safety parameters will be observed on day 21.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BT200</intervention_name>
    <description>BT200 is a PEGylated synthetic RNA oligonucleotide</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:To be eligible for this study, patients must meet all of the following&#xD;
        inclusion criteria:&#xD;
&#xD;
          1. Hereditary bleeding disorder:&#xD;
&#xD;
               -  Congenital hemophilia A without inhibitors with a prophylactic treatment regime&#xD;
&#xD;
               -  Heterozygous carriers of hemophilia A with subnormal FVIII levels&#xD;
&#xD;
               -  VWD Type 1, &quot;Vicenza&quot; type&#xD;
&#xD;
               -  VWD Type 2b&#xD;
&#xD;
          2. Male or female, age â‰¥18-70 years old at Screening&#xD;
&#xD;
          3. If female, must be post-menopausal or surgically sterilized&#xD;
&#xD;
          4. Able to comprehend and to give informed consent&#xD;
&#xD;
          5. Able to cooperate with the Investigator, to comply with the requirements of the study,&#xD;
             and to complete the full sequence of protocol-related procedures -&#xD;
&#xD;
        Exclusion Criteria: Patients meeting any of the following criteria will be excluded from&#xD;
        the study:&#xD;
&#xD;
          1. Clinically significant medical history or ongoing chronic illness that would&#xD;
             jeopardize the safety of the patient or compromise the quality of the data derived&#xD;
             from his/her participation in this study&#xD;
&#xD;
          2. Medical History of spontaneous (not FVIII or FEIBA-associated) venous or arterial&#xD;
             thromboembolic events&#xD;
&#xD;
          3. History of significant drug allergy or anaphylactic reactions&#xD;
&#xD;
          4. Substance abuse, mental illness, or any reason that makes it unlikely in the judgment&#xD;
             of the Investigator for the patient to be able to comply fully with study procedures&#xD;
&#xD;
          5. Use of medication during 2 weeks before the start of the study, which in the judgment&#xD;
             of the Investigator may adversely affect the patient's welfare or the integrity of the&#xD;
             study's results&#xD;
&#xD;
          6. Concurrent treatment with other experimental drugs or participation in another&#xD;
             clinical trial with any investigational drug within 30 days or 5 elimination&#xD;
             half-lives (whichever is longer) prior to treatment start -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulla Derhaschnig, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MU Vienna, Dept. of Clinical Pharmacology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2020</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Ulla Derhaschnig, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Hemophilia A</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
    <mesh_term>Von Willebrand Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

